People who have amyotrophic lateral sclerosis (ALS) know how hard it can be to communicate, but a new app developed by Microsoft researchers, called GazeSpeak, may make speaking with the eyes a reality. GazeSpeak, to be unveiled in May at the Conference on Human Factors in Computing…
News
Researchers have developed a method to measure the effectiveness of a process of RNA destruction that clears abnormal molecules from cells. Since abnormally high production of junk RNA has been thought to contribute to amyotrophic lateral sclerosis (ALS), the method can be used to screen for drugs that may boost…
The fitness franchise Orangetheory Fitness has partnered with Augie’s Quest to raise $1 million over the next two weeks for amyotrophic lateral sclerosis (ALS) research. During the campaign (#IBurnForALS) — which lasts from February 20 to March 5 — more than 570 Orangetheory studios nationwide will encourage their members…
If parents pass on mutations in the C9orf72 gene, their children not only develop amyotrophic lateral sclerosis (ALS) or frontotemporal dementia but do so at an earlier age due to an expansion of the mutation. This finding makes it easier for physicians to determine when to start monitoring an individual carrying a C9orf72…
Two French researchers, Martine Barkats and Maria-Grazia Biferi, are winners of the Avi Kremer ALS Treatment Prize, worth $1 million, for developing a gene therapy approach that shows promise in treating certain types of amyotrophic lateral sclerosis (ALS), Prize4Life announced in a recent press release. The approach targets one of the…
Neuraltus Pharmaceuticals has enrolled 50 of the 120 patients it hopes to obtain for a confirmatory Phase 2 clinical trial evaluating NP001 as a treatment for amyotrophic lateral sclerosis (ALS). Completion of enrollment is expected in mid-2017, with Neuraltus shooting for results in early 2018. Eighteen clinical sites across North…
Researchers have developed a molecule called 123C4 that targets the EphA4 receptor, which is known to contribute to the development of amyotrophic lateral sclerosis (ALS), according to a new study. The paper, “Potent and Selective Epha4 Agonists for the Treatment of ALS,” appeared in the journal Cell Chemical Biology. Its…
Patients with chronic conditions like amyotrophic lateral sclerosis (ALS) are as concerned as the general population about health care costs, but see benefits in the Affordable Care Act (ACA) that the healthy may have overlooked, a poll indicates. These findings are reported in a new large-scale poll assessing patient…
Swiss drugmaker GeNeuro has signed an agreement with the National Institute of Neurological Disorders and Stroke (NINDS) — part of the U.S. National Institutes of Health (NIH) — to advance studies of its novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis (ALS). Under the Cooperative Research and Development Agreement, GeNeuro will…
Heavy metal pollution may not be as important as previously thought in the development of amyotrophic lateral sclerosis (ALS), according to new research by Italian scientists.
Recent Posts
- New rare gene variants tied to ALS risk in large international genetic analysis
- ALS patients, caregivers prefer team-based care model, new survey finds
- ALS partnership to give 6 patients expanded access to TRE-515
- Frustration mounts when ALS assistive technology isn’t so helpful
- Trial of experimental ALS therapy pridopidine enrolls first participant